Journal of Cancer Research and Cellular Interventions (JCCRCI)

OLITES PUBLISHERS
A Global Approach For Research

Open Access

Research Article

A Silent Storm in the Bone Marrow: Understanding Acute Myeloid Leukemia

Kiessling F, Romanski T, Lichtenstein R, Rowan Y, Feldman E

The Institute of Molecular Medicine, Russia

***Corresponding Author:** Rowan Y, The Institute of Molecular Medicine, Russia
Citation: Rowan Y (2026). The Institute of Molecular Medicine, Russia V1(4)

Received date: March28, 2026**: Accepted date:** April 09, 2026**: Published date:** April15,2026
Keywords: molecular biology, myeloid precursor cells, hematopoietic stem cells, myelodysplastic syndromes, genetic abnormalities

Abstract
Acute Myeloid Leukemia (AML) is a rapidly progressing hematological malignancy characterized by the uncontrolled proliferation of immature myeloid cells in the bone marrow and peripheral blood. This disorder disrupts normal hematopoiesis, leading to life-threatening complications such as anemia, infection, and bleeding. Despite advances in molecular biology and targeted therapies, AML remains a complex disease with heterogeneous genetic profiles and variable clinical outcomes. This article explores the pathophysiology, risk factors, clinical manifestations, diagnostic approaches, and evolving treatment strategies of AML, highlighting recent progress and ongoing challenges in improving patient survival and quality of life.

Introduction
Acute Myeloid Leukemia (AML) is one of the most aggressive forms of leukemia, primarily affecting adults but also occurring in children. It originates in the bone marrow the primary site of blood cell production where abnormal myeloid precursor cells multiply uncontrollably and fail to mature into functional blood cells. The rapid accumulation of these immature cells, known as blasts, interferes with normal blood cell production and leads to systemic complications.

Pathophysiology
AML arises due to genetic mutations that disrupt normal cell differentiation and proliferation. These mutations affect hematopoietic stem cells, causing them to produce abnormal myeloblasts. Instead of maturing into red blood cells, white blood cells, or platelets, these blasts accumulate in the bone marrow and spill into the bloodstream. Common genetic abnormalities associated with AML include chromosomal translocations, gene mutations such as FLT3, NPM1, and CEBPA, and epigenetic alterations. These molecular changes not only drive disease progression but also influence prognosis and therapeutic response

Risk Factors
Several factors increase the risk of developing AML:

- **Age:** Most common in individuals over 60 years
- **Previous chemotherapy or radiation therapy**
- **Exposure to toxic chemicals such as benzene**
- **Smoking**
- **Genetic disorders like Down syndrome**
- **Pre-existing blood disorders** such as myelodysplastic syndromes

Clinical Manifestations
The symptoms of AML are often nonspecific and develop rapidly due to bone marrow failure

- **Anemia:** Fatigue, pallor, shortness of breath
- **Neutropenia:** Frequent infections and fever
- **Thrombocytopenia:** Easy bruising, bleeding gums, petechiae
- **Bone pain or joint discomfort**
- **Swollen lymph nodes or spleen (in some cases)**

Because these symptoms can resemble other conditions, early diagnosis can be challenging

Journal ofCancer Research and Cellular Interventions (JCCRCI)

Diagnosis

The diagnosis of AML involves a combination of laboratory and clinical assessments:

- **Complete Blood Count (CBC):** Reveals abnormal levels of blood cells
- **Peripheral Blood Smear:** Identifies blast cells
- **Bone Marrow Aspiration and Biopsy:** Confirms diagnosis and assesses blast percentage
- **Cytogenetic and Molecular Testing:** Detects genetic abnormalities and guides treatment decisions

According to diagnostic criteria, AML is typically confirmed when ≥20% blasts are present in the bone marrow or blood.

Treatment Strategies

Treatment of AML depends on factors such as age, overall health, and genetic profile of the disease. The primary goal is to achieve remission by eliminating leukemic cells.

Induction Therapy

This is the initial phase aimed at achieving complete remission. It usually involves intensive chemotherapy, commonly referred to as the "7+3" regimen (cytarabine plus an anthracycline).

Consolidation Therapy

After remission, additional treatment is given to eliminate residual disease and prevent relapse. This may include

- High-dose chemotherapy
- Stem cell transplantation (especially in high-risk patients)

Targeted Therapy

Advancements in molecular research have led to targeted drugs such as FLT3 inhibitors, IDH inhibitors, and BCL-2 inhibitors, which specifically attack leukemia cells with certain mutations

Supportive Care

Supportive treatments play a crucial role and include:

- Blood transfusions
- Antibiotics for infections
- Growth factors to stimulate blood cell production

Prognosis

The prognosis of AML varies widely. Younger patients and those with favorable genetic mutations tend to have better outcomes, while older patients or those with high-risk cytogenetics face poorer survival rates. Despite improvements in therapy, relapse remains a significant challenge

Recent Advances and Future Directions

Recent developments in genomics and precision medicine have transformed AML management. Personalized treatment approaches based on genetic profiling are becoming standard practice. Immunotherapies, including monoclonal antibodies and CAR-T cell therapy, are under investigation and hold promise for future treatment.

Additionally, minimal residual disease (MRD) monitoring is improving the ability to detect relapse early and tailor treatment accordingly.

Conclusion

Acute Myeloid Leukemia is a complex and rapidly progressing cancer that demands prompt diagnosis and aggressive treatment. While traditional chemotherapy remains the backbone of therapy, emerging targeted treatments and personalized medicine approaches are reshaping the landscape of AML care. Continued research and innovation are essential to improve survival outcomes and ultimately find a cure for this challenging disease

References

1. Cui, X.Y.; Skretting, G.; Jing, Y.; Sun, H.; Sandset, P.M.; Sun, L. Hypoxia influences stem cell-like properties in multidrug resistant K562 leukemic cells. Blood Cells Mol. Dis. 2013, 51, 177–184.
2. Olsson, L.; Zettermark, S.; Biloglav, A.; Castor, A.; Behrendtz, M.; Forestier, E.; Paulsson, K.; Johansson, B. The genetic landscape of paediatric de novo acute myeloid leukaemia as defined by single nucleotide polymorphism array and exon sequencing of 100 candidate genes. Br. J. Haematol. 2016, 174, 292–301
3. Hernandez-Valladares, M.; Aasebø, E.; Selheim, F.; Berven, F.S.; Bruserud, Ø. Selecting sample preparation workflows for mass spectrometry-based proteomic and phosphoproteomic analysis of patient samples with acute myeloid leukemia. Proteomes 2016, 4, 24.

4. Tyanova, S.; Temu, T.; Sinitcyn, P.; Carlson, A.; Hein, M.Y.; Geiger, T.; Mann, M.; Cox, J. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 2016, 13, 731–740.
5. Shiiyama, R.; Fukushima, S.; Jinnin, M.; Yamashita, J.; Miyashita, A.; Nakahara, S.; Kogi, A.; Aoi, J.; Masuguchi, S.; Inoue, Y.; et al. Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. Melanoma Res. 2013, 23, 366–372.
6. Tsuchiyama, J.; Yoshino, T.; Mori, M.; Kondoh, E.; Oka, T.; Akagi, T.; Hiraki, A.; Nakayama, H.; Shibuya, A.; Ma, Y.; et al. Characterization of a novel human natural killer-cell line (NK-YS) established from natural killer cell lymphoma/leukemia associated with Epstein-Barr virus infection. Blood 1374, 92, 1374–1383.

Journal ofCancer Research and Cellular Interventions (JCCRCI)